Daniel Campos-Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Campos-Fernández has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Elena Fonseca
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
14 shared publications - Laura Abraira
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
11 shared publications - Estevo Santamarina
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
8 shared publications - Manuel Quintana
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
8 shared publications - Manuel Toledo
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
8 shared publications - Sofía Lallana
Epilepsy Unit, Neurology Department. Vall d'Hebron Hospital Universitat Autònoma de Barcelona Barcelona Spain
8 shared publications
Latest Publications
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Cenobamate in Focal-Onset Refractory and Super-Refractory Status Epilepticus
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Cenobamate in Focal-Onset Refractory and Super-Refractory Status Epilepticus
- Open Access
- 24 July 2026
- Published by Elsevier in Neurología
- Vol. 41 (7)
Valor semiológico de los movimientos rítmicos ictales no clónicos de la mano (RINCH) en las crisis epilépticas
- 24 July 2026
- Published by Elsevier in Neurología
- Vol. 41 (7)
Open AccessValor semiológico de los movimientos rítmicos ictales no clónicos de la mano (RINCH) en las crisis epilépticas
Long‐term mortality after status epilepticus: A 5‐year analysis study
Objective: To describe 5‐year mortality after status epilepticus (SE) and identify factors associated with long‐term survival. We also validated the prognostic performance of the Age, Consciousness, Duration (ACD) score and evaluated long‐term survival across etiological categories defined by the Lattanzi classification of acute symptomatic SE. Methods: Retrospective cohort analysis of a prospectively maintained database of consecutive patients ≥16 years of age with confirmed SE admitted to a tertiary epilepsy center (2011–2022). We excluded unclear diagnoses, hypoxic–anoxic etiologies, and incomplete follow‐up. We recorded clinical variables and prognostic scores modified Status Epilepticus Severity Score (mSTESS), Epidemiology‐based Mortality Status Epilepticus (EMSE), and Age, Consciousness, Duration (ACD). Mortality was assessed at discharge and annually up to 5 years. Results: We included 786 patients (mean age 63.4 years, 43.5% female). Five‐year mortality was 50.3%, with 44.0% of deaths occurring within the first 2 years. Neurological causes accounted for 60.8% of deaths, and direct seizure‐related causes represented 74.6% of neurological deaths. Independent predictors of higher long‐term mortality were older age, higher premorbid mRS, absence of prior seizure history, comorbidity burden, systemic complications, and impaired consciousness during SE; convulsive and focal motor SE were associated with lower mortality risk. mSTESS and EMSE were associated with long‐term mortality. In patients with less damaging etiologies, ACD predicted 5‐year mortality (hazard ratio [HR] 1.163, 95% confidence interval [CI] 1.063–1.273; area under the curve [AUC] 0.717); ACD ≥10 corresponded to >50% 2‐year mortality. Five‐year mortality was 61.3% (acute‐primary Central Nervous System (CNS) and 58.3% (acute‐secondary CNS). Significance: SE carries substantial long‐term mortality, particularly within the first 2 years. Neurological and seizure‐related causes were the most frequent. The Lattanzi classification and the ACD score retained long‐term prognostic value.
Long‐term mortality after status epilepticus: A 5‐year analysis study
Objective: To describe 5‐year mortality after status epilepticus (SE) and identify factors associated with long‐term survival. We also validated the prognostic performance of the Age, Consciousness, Duration (ACD) score and evaluated long‐term survival across etiological categories defined by the Lattanzi classification of acute symptomatic SE. Methods: Retrospective cohort analysis of a prospectively maintained database of consecutive patients ≥16 years of age with confirmed SE admitted to a tertiary epilepsy center (2011–2022). We excluded unclear diagnoses, hypoxic–anoxic etiologies, and incomplete follow‐up. We recorded clinical variables and prognostic scores modified Status Epilepticus Severity Score (mSTESS), Epidemiology‐based Mortality Status Epilepticus (EMSE), and Age, Consciousness, Duration (ACD). Mortality was assessed at discharge and annually up to 5 years. Results: We included 786 patients (mean age 63.4 years, 43.5% female). Five‐year mortality was 50.3%, with 44.0% of deaths occurring within the first 2 years. Neurological causes accounted for 60.8% of deaths, and direct seizure‐related causes represented 74.6% of neurological deaths. Independent predictors of higher long‐term mortality were older age, higher premorbid mRS, absence of prior seizure history, comorbidity burden, systemic complications, and impaired consciousness during SE; convulsive and focal motor SE were associated with lower mortality risk. mSTESS and EMSE were associated with long‐term mortality. In patients with less damaging etiologies, ACD predicted 5‐year mortality (hazard ratio [HR] 1.163, 95% confidence interval [CI] 1.063–1.273; area under the curve [AUC] 0.717); ACD ≥10 corresponded to >50% 2‐year mortality. Five‐year mortality was 61.3% (acute‐primary Central Nervous System (CNS) and 58.3% (acute‐secondary CNS). Significance: SE carries substantial long‐term mortality, particularly within the first 2 years. Neurological and seizure‐related causes were the most frequent. The Lattanzi classification and the ACD score retained long‐term prognostic value.
- 5 June 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 140, 143-148
Delirium in critically ill patients treated with levetiracetam or brivaracetam: a comparative study
- 5 June 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 140, 143-148
Delirium in critically ill patients treated with levetiracetam or brivaracetam: a comparative study
- 9 May 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 181, 111090
Self-reported quality of life outcomes after Cenobamate initiation
- 9 May 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 181, 111090
Self-reported quality of life outcomes after Cenobamate initiation
- Open Access
Extracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus
Objective: This study was undertaken to identify novel blood‐based biomarkers associated with the early diagnosis of status epilepticus (SE) by exploring proteomic alterations in plasma extracellular vesicles (EVs). Methods: We conducted an observational and prospective study in a two‐phase design: a discovery proteomic analysis of plasma EVs from 16 patients (eight with SE and eight matched non‐SE), followed by a validation phase using basic immunodetection techniques in a separate cohort of 160 patients (80 SE, 80 non‐SE) for selected proteins in plasma. Proteomic profiling was performed with liquid chromatography–tandem mass spectrometry, and protein interaction networks were explored using STRING and Cytoscape software platforms. Results: In the discovery phase, 2046 proteins were identified, and 977 met inclusion criteria. CDH1, APOC4, and IGHG2 showed the highest differential expression in SE patients. Network analysis revealed strong interactions involving SLC4A1 and SRC. In the validation cohort, levels of APOC4, CDH1, SLC4A1, and S100B were significantly higher in SE patients ( p < .05). In the multivariate logistic regression model, only APOC4, S100B, and SLC4A1 remained independently associated with SE diagnosis. A combined model including these proteins predicted SE with 84.6% accuracy (95% confidence interval = 64.3%–94.9%). Other proteins, including NSE and HMGB1, showed no significant differences. Significance: This study identifies new plasma biomarkers that may support the early diagnosis of SE, particularly in emergency settings where access to electroencephalography is limited. These findings suggest potential applicability to clinical practice; nevertheless, prospective validation in independent and larger cohorts is required.
Open AccessExtracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus
Objective: This study was undertaken to identify novel blood‐based biomarkers associated with the early diagnosis of status epilepticus (SE) by exploring proteomic alterations in plasma extracellular vesicles (EVs). Methods: We conducted an observational and prospective study in a two‐phase design: a discovery proteomic analysis of plasma EVs from 16 patients (eight with SE and eight matched non‐SE), followed by a validation phase using basic immunodetection techniques in a separate cohort of 160 patients (80 SE, 80 non‐SE) for selected proteins in plasma. Proteomic profiling was performed with liquid chromatography–tandem mass spectrometry, and protein interaction networks were explored using STRING and Cytoscape software platforms. Results: In the discovery phase, 2046 proteins were identified, and 977 met inclusion criteria. CDH1, APOC4, and IGHG2 showed the highest differential expression in SE patients. Network analysis revealed strong interactions involving SLC4A1 and SRC. In the validation cohort, levels of APOC4, CDH1, SLC4A1, and S100B were significantly higher in SE patients ( p < .05). In the multivariate logistic regression model, only APOC4, S100B, and SLC4A1 remained independently associated with SE diagnosis. A combined model including these proteins predicted SE with 84.6% accuracy (95% confidence interval = 64.3%–94.9%). Other proteins, including NSE and HMGB1, showed no significant differences. Significance: This study identifies new plasma biomarkers that may support the early diagnosis of SE, particularly in emergency settings where access to electroencephalography is limited. These findings suggest potential applicability to clinical practice; nevertheless, prospective validation in independent and larger cohorts is required.
- Open Access
- 15 September 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (2) , 480-493
Persistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor
Objectives/Background: Persistent headache (PH) after an aneurysmal subarachnoid hemorrhage (aSAH) and the influence of migraine history (MH) on its evolution and prognosis is poorly understood. Our study aims are to (1) determine the prevalence, characteristics, and prognostic factors of PH after aSAH; and (2) study the impact of personal MH on PH and aSAH prognosis. Methods: This retrospective cohort study included all adults with confirmed aSAH from January 2019 to September 2021 at a tertiary hospital. Data collected included demographics, comorbidities (including personal MH before aSAH), complementary tests, and aneurysm characteristics. The following clinical, radiological, and functional assessment scales were used: Glasgow Coma Scale (GCS), World Federation of Neurosurgical Societies (WFNS) grading scale, Hunt and Hess grading system, modified Fisher scale, VASOGRADE score, APACHE II score, and the modified Rankin Scale (mRS). PH was defined following the definition of persistent headache attributed to past nontraumatic subarachnoid hemorrhage (6.2.4.2) in the International Classification of Headache Disorders, 3rd edition. PH characteristics were assessed via phone interviews. Descriptive analyses were conducted, along with group comparisons and regression models exploring associations between MH, PH, functional outcomes, and survival. Results: A total of 130 individuals with aSAH were included with a median age of 59.0 (interquartile range, 51.0–70.0) years and 62.3% (81 of 130) were female. For PH assessment, a total of 36.9% (48 of 130) individuals were excluded due to death, and 19.5% (16 of 82) due to lack of phone availability, resulting in a final sample of 66 individuals. PH had a prevalence of 47.0% (31 of 66) at a mean‐time follow up of 3.12 ± 0.83 years. PH primarily manifested with moderate intensity (median visual analogue scale, 7), bilateral localization (51.6%; 16 of 31), and oppressive quality (77.4%; 24 of 31), with a minority of individuals experiencing nausea/vomiting (29.0%; 9 of 31) or photo/phonophobia (41.9%; 13 of 31). Up to 61.3% (19 of 31), referred moderate–severe interference of PH on daily activities. A personal MH was the only risk factor for developing PH (adjusted odds ratios [aOR], 3.9; 95% confidence interval [CI], 1.24–13.2; p = 0.022), and was present in up to 48.5% individuals (32 of 66). MH was associated with decreased aSAH clinical severity risk in both Hunt and Hess (adjusted p [adj. p ] = 0.038) and WFNS (adj. p = 0.038) scales, better function outcomes (mRS) at discharge and at 3 months of follow‐up (adj. p = 0.002 and adj. p = 0.003), and was independently associated with aSAH survival (aOR, 3.3; 95% CI, 1.14–11.06; p = 0.037). Conclusion: Persistent headache affected up to 47% individuals in the long term following aSAH and significantly impacted their quality of life. A history of migraine appeared to be more common among individuals with aSAH and was associated with a three‐fold increase in survival (aOR, 3.3); however, it also served as a risk factor for developing PH.
- 15 September 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (2) , 480-493
Open AccessPersistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor
Objectives/Background: Persistent headache (PH) after an aneurysmal subarachnoid hemorrhage (aSAH) and the influence of migraine history (MH) on its evolution and prognosis is poorly understood. Our study aims are to (1) determine the prevalence, characteristics, and prognostic factors of PH after aSAH; and (2) study the impact of personal MH on PH and aSAH prognosis. Methods: This retrospective cohort study included all adults with confirmed aSAH from January 2019 to September 2021 at a tertiary hospital. Data collected included demographics, comorbidities (including personal MH before aSAH), complementary tests, and aneurysm characteristics. The following clinical, radiological, and functional assessment scales were used: Glasgow Coma Scale (GCS), World Federation of Neurosurgical Societies (WFNS) grading scale, Hunt and Hess grading system, modified Fisher scale, VASOGRADE score, APACHE II score, and the modified Rankin Scale (mRS). PH was defined following the definition of persistent headache attributed to past nontraumatic subarachnoid hemorrhage (6.2.4.2) in the International Classification of Headache Disorders, 3rd edition. PH characteristics were assessed via phone interviews. Descriptive analyses were conducted, along with group comparisons and regression models exploring associations between MH, PH, functional outcomes, and survival. Results: A total of 130 individuals with aSAH were included with a median age of 59.0 (interquartile range, 51.0–70.0) years and 62.3% (81 of 130) were female. For PH assessment, a total of 36.9% (48 of 130) individuals were excluded due to death, and 19.5% (16 of 82) due to lack of phone availability, resulting in a final sample of 66 individuals. PH had a prevalence of 47.0% (31 of 66) at a mean‐time follow up of 3.12 ± 0.83 years. PH primarily manifested with moderate intensity (median visual analogue scale, 7), bilateral localization (51.6%; 16 of 31), and oppressive quality (77.4%; 24 of 31), with a minority of individuals experiencing nausea/vomiting (29.0%; 9 of 31) or photo/phonophobia (41.9%; 13 of 31). Up to 61.3% (19 of 31), referred moderate–severe interference of PH on daily activities. A personal MH was the only risk factor for developing PH (adjusted odds ratios [aOR], 3.9; 95% confidence interval [CI], 1.24–13.2; p = 0.022), and was present in up to 48.5% individuals (32 of 66). MH was associated with decreased aSAH clinical severity risk in both Hunt and Hess (adjusted p [adj. p ] = 0.038) and WFNS (adj. p = 0.038) scales, better function outcomes (mRS) at discharge and at 3 months of follow‐up (adj. p = 0.002 and adj. p = 0.003), and was independently associated with aSAH survival (aOR, 3.3; 95% CI, 1.14–11.06; p = 0.037). Conclusion: Persistent headache affected up to 47% individuals in the long term following aSAH and significantly impacted their quality of life. A history of migraine appeared to be more common among individuals with aSAH and was associated with a three‐fold increase in survival (aOR, 3.3); however, it also served as a risk factor for developing PH.
- 20 June 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 163-171
Predicting seizure recurrence after status epilepticus: a multicenter exploratory machine learning approach
- 20 June 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 163-171
Predicting seizure recurrence after status epilepticus: a multicenter exploratory machine learning approach
- 29 November 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 163, 110158
Trends in antiseizure medication prescription in Idiopathic generalized epilepsy over the last 10 years
- 29 November 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 163, 110158
Trends in antiseizure medication prescription in Idiopathic generalized epilepsy over the last 10 years
- 26 November 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (10) , e209630
Author Response: Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE Score
- 26 November 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (10) , e209630
Author Response: Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE Score